Monoclonal antibody treatment for COVID-19 in kidney transplant recipients is associated with improved survival and decreased risk for hospitalization, according to study findings presented at the 2022 American Transplant Congress (ATC 2022) in Boston, Massachusetts.
The findings are from a retrospective study that included 291 kidney transplant recipients who tested positive for SARS-CoV-2, the coronavirus that causes COVID-19. Of these, 120 (41%) received monoclonal antibody treatment. Investigators excluded from their analysis 1 patient who died from causes unrelated to COVID-19.
Patients who received monoclonal antibodies had a significantly higher survival rate compared with those who did not (99.2% vs 82.4%) as well as a significantly lower hospitalization rate (18.3% vs 60.8%), Nicole M. Ali, MD, of NYU Langone Health Transplant Institute in New York, New York, and colleagues reported.
Continue Reading
Further, the investigators observed that completion of a vaccine series — defined as 2 doses of an mRNA vaccine or 1 dose of the Janssen adenovirus vaccine — prior to infection with SARS-CoV-2 also was associated with a higher survival rate (98.6% vs 80.3%) and lower hospitalization rate (27.1% vs 59.2%).
Monoclonal antibody therapy combined with completed vaccination significantly reduced the hospitalization rate compared with monoclonal antibody therapy alone (14.0% vs 26.8%), according to the investigators.
Reference
Ali NM, Tatapudi V, Chand R, Sureau K, Mehta S, Montgomery R. The impact of monoclonal antibody against Sars-CoV2 and vaccination on outcomes in kidney transplant recipients with Covid-19. Presented at: ATC 2022; June 4-8, 2022. Abstract 9012.
